Myo-inositol trispyrophosphate (ITPP) is inositol phosphate, a pyrophosphate, a drug candidate, and improves the performance of suspected substances, which exerts biological effects by increasing tissue oxygenation.
ITPP is the membrane-permeant allosteric regulator of hemoglobin which somewhat reduces the oxygen-binding affinity, which shifts the oxygen hemoglobin dissociation curve to the right and thereby increasing the release of oxygen from the blood into the tissues.
The phytic acid, on the contrary, is not membrane-permeant because of its charge distribution. You can buy supplements from www.taylormadeequine.com/product/itpp/.
Studies of mice in vivo showed an increase in dose-dependent tissue oxygenation and increase endurance during physical exercise, both healthy mice and transgenic mice that express the phenotype of heart failure.
This substance is believed to have a high potential for use in athletic doping, and liquid chromatography-mass spectrometry tests have been developed to detect ITPP in a urine test.
Its use as a performance-enhancing substance has also been suspected of horse racing and similar tests have been developed for horses.
ITPP has researched the use of a potential adjuvant in cancer treatment in conjunction with chemotherapy, because of its impact in reducing tissue hypoxia.
The human clinical trials registered in 2014 under the number OXY111A compound. This substance has also been examined in the context of other diseases involving hypoxia, such as cardiovascular disease and dementia.